top of page
Writer's pictureFeatdoor Agency

Reflections of the Increase in Pharmaceutical Prices on theSector

Innovations in the pharmaceutical market make it possible to treat and prevent many diseases.

Pharmaceutical innovations entail certain mandatory costs that must be utilised in research and

development. The right to equal access to medicines is a social value. The cost of medicines and

global spending on medicines can make it difficult to achieve this social value. Increasing demand

for medicines and rising medicine prices create a major challenge for the health system.

Increases in medicine prices can also cause health system problems by displacing investments in

other necessary care services for patients.

In particular, the use of a single drug in the treatment of some diseases can potentially lead to the

pharmaceutical manufacturer retaining market power. Patented medicines may have high prices

because they have no suitable alternatives and face no competition. At the same time, medicine

prices can vary considerably between different countries. Differentiating final prices by country

prevents everyone from demanding the lowest available price.

In addition, expected increases in medicine prices may lead to stockpiling. Stockpiling of

medicines by companies and some distribution organisations may lead to patients not being able

to find the medicines they are looking for and their treatment may be disrupted.

When a new pharmaceutical product is discovered, a patent incentivises the manufacturer's

investment in research. Patents can help establish a fair balance in the pharmaceutical market,

but monopolisation that occurs until the patent expires can lead to high prices for the

manufacturer. In short, the manufacturer of an original medicine can significantly increase prices

when it is not facing competition and the treatment is necessary. This may continue until a

competitor enters the market.


Factors Affecting the Increase in Pharmaceutical Prices

Manufacturer control over the price of a medicine can be indirect or direct. When setting medicine

prices directly, pharmaceutical companies focus on several different factors. These are

- The uniqueness of the medicine

- Competition situation

- Efficacy of the medicine

- Research and development costs

If the producer cannot determine the price directly, a bargaining takes place between the

producer and the regulator. The price is determined as a result of the negotiations. In some

countries, such as Germany and Denmark, medicine prices can be set freely. In these countries,

some additional measures are used to control pharmaceutical expenditures. Price reductions and

price freezes are examples of these additional measures. In some countries, such as Italy and

Greece, the prices of medicines are set according to certain criteria.

An increase in the price of medicines leads to competition, which serves to drive down prices.

The same pricing has a major impact on the potential for success. For example, a high price may

make payers reluctant to pay for a medicine. Similarly, doctors may be reluctant to prescribe a

drug with a very high price but little effect.

The introduction of a generic, i.e. equivalent, medicine may lead to a decrease in prices. A

generic medicine is a copy of a medicine whose patent protection has expired, produced with the

same active ingredient. Generic medicines have an extremely important role in lowering prices.

This reduction enables patients to access affordable medicines and saves money on healthcare

services provided by public institutions. In summary, the introduction of a generic medicine to the

market puts pressure on the original medicine.


Approaches to Price Competition in the Pharmaceutical

Industry in Different Countries


Direct price controls may be provided by the regulator to ensure price competition in the

pharmaceutical sector. The prices set may vary depending on the conditions of the countries.

Examples include countries such as Spain and France. It should be kept in mind that excessively

low drug prices may also lead to an increase in consumption. Moreover, direct intervention of the

authority may cause R&D activities, which are of vital importance for pharmaceutical

manufacturers, to lose their quality, new medicines may not be produced and, as a consequence,

the generic market may not develop. Therefore, the medicine pricing policy determined by the

unilateral authority may not always have the expected effect.

In order to prevent high increases in medicine prices, some countries, such as the UK, Portugal

and France, require that cost and efficacy analyses of the medicine be submitted to the price-

setting authorities.

Another approach to indirect price control is profit control. This method, used in some countries

such as Turkey, the UK and Korea, involves controlling the profit level of the manufacturer or

product that produces the medicine. Increases in pharmaceutical prices also have significant

effects on Turkey's position in the sector. Especially for imported medicines, price increases

affect costs.

In order to increase the applicability of equitable health policies and to encourage innovation, the

health sector requires policies that ensure that price competition is as fair as possible. In this

sense, decisions can be taken to prevent unfair pricing and remove barriers to access. Policies

that provide price controls, while enabling access to health and essential medicines, bring other

problems. As a result, there is a need for price competition in the pharmaceutical sector, as in

every sector. You can contact Sina Pharmaceutical Warehouse, which has 25 years of industry

experience and an expert team, to learn more about pharmaceutical exports and the sector.

2 views

Recent Posts

See All

Comments


bottom of page